SEC Form 4 · accession 0001144204-16-074089
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Miri Ben-Ami
Officer — See Remarks*
Period of report
Jan 1, 2016
Accepted (ET)
Jan 5, 2016 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $0.73 | Jan 1, 2016 | A | 400,000 | A | — | Jan 1, 2026 | Common Stock | 400,000 | 400,000 | D |
Explanation of responses
- F1The stock options shall vest over a period of three years, with 1/3 of the stock options vesting on the first anniversary of the date of grant and the remainder vesting quarterly over the following two-year period.
Remarks
*President of Immune Pharmaceuticals Ltd. and Head of Oncology